Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and-3)

导出原文传递

翻译打印收藏纠错

作者： Blauvelt, Andrew ^[1] ; Papp, Kim A. ^[2] ; Griffiths, Christopher E. M. ^[3] ; Puig, Luis ^[4] ; Weisman, Jamie ^[5] ; Dutronc, Yves ^[6] ; Kerr, Lisa Farmer ^[7] ; Ilo, Dapo ; Mallbris, Lotus ; Augustin, Matthias

作者单位： Univ Med Ctr Hamburg Eppendorf, Inst Hlth Serv Res Dermatol & Nursing IVDP, Hamburg, Germany ^[1] Med Dermatol Specialists Inc, Atlanta, GA USA ^[2] Univ Manchester, Salford Royal Hosp, Manchester Acad Hlth Sci Ctr, Dermatol Ctr, Manchester, Lancs ^[3] Oregon Med Res Ctr, 9495 SW Locust St,Suite G, Portland, OR 97223 USA ^[4] K Papp Clin Res & Prob Med Res, Waterloo, ON, Canada ^[5] Eli Lilly & Co, Indianapolis, IN 46285 USA ^[6] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain ^[7]

发布时间 2017-05-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

American journal of clinical dermatology

2017年18卷2期

273-280页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and-3)

American journal of clinical dermatology

相似文献

American journal of clinical dermatology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and-3)

American journal of clinical dermatology

相似文献

American journal of clinical dermatology

相关期刊

检索历史清除